Mitochondrial Support Protocol

Overview

Mitochondrial dysfunction sits at the center of many age-related pathologies — sarcopenia, insulin resistance, neurodegeneration, and generalized fatigue. Interventions that target mitochondrial biogenesis, membrane integrity, and redox capacity have therefore become a major focus in both longevity research and performance medicine.

This protocol combines three mechanistically complementary tools. MOTS-c is a mitochondrial-derived peptide that promotes metabolic flexibility and AMPK activation. SS-31 (elamipretide) binds cardiolipin and stabilizes the inner mitochondrial membrane, improving electron transport efficiency. NAD+ precursors raise intracellular NAD+, a rate-limiting cofactor for sirtuin activity and oxidative phosphorylation.

The protocol assumes a reasonable training stimulus and a dietary pattern that supports metabolic health; no peptide compensates for sedentary behavior or chronic caloric excess.

Compounds Involved

MOTS-c

MOTS-c is encoded within mitochondrial DNA and signals systemically to improve glucose disposal and fatty acid oxidation. Research has shown improvements in insulin sensitivity and exercise capacity in preclinical models. It pairs well with training, as its effects are amplified by the same upstream pathways (AMPK, PGC-1α) that exercise activates.

SS-31 (Elamipretide)

SS-31 selectively targets the inner mitochondrial membrane via cardiolipin binding. Unlike generic antioxidants, it improves electron transport chain coupling rather than merely quenching reactive species. Early human trials have examined it in primary mitochondrial disease and heart failure.

NAD+ / Precursors

Direct NAD+ IVs are popular but costly; oral nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN) at 300–500 mg/day is a more sustainable baseline strategy. Serum and intracellular NAD+ both decline with age.

Protocol Structure

Phase 1 — Foundation (Weeks 1–2)

• NAD+ precursor (NR 300 mg or NMN 500 mg) daily, with morning meal
• CoQ10 ubiquinol 100 mg/day, PQQ 10 mg/day with a fat-containing meal
• Zone 2 cardio 3x/week, 30–45 minutes — this is a non-negotiable substrate for mitochondrial adaptation
• Resistance training 2–3x/week
• Time-restricted eating 12–14 hour window if tolerated

Phase 2 — Peptide Layer (Weeks 3–12)

• MOTS-c 5–10 mg subcutaneous, 2–3 times weekly (e.g. Monday / Wednesday / Friday)
• SS-31 2–5 mg subcutaneous daily, or 5 mg 3x/week depending on goals and budget
• Continue NAD+ precursor and cofactors
• Consider a 1–2 gram oral NAC daily for glutathione substrate during heavy training

Phase 3 — Maintenance (Weeks 13+)

• Cycle MOTS-c: 8 weeks on, 4 weeks off
• SS-31 can be dropped to 2–3x/week maintenance or paused during off-cycles
• Retain NAD+ precursor, CoQ10, PQQ as ongoing baseline
• Reassess subjective energy, training capacity, and — if available — VO2max or RMR every 12 weeks

Session Timing

• Inject MOTS-c pre-workout on training days to layer its AMPK effect on the training stimulus
• SS-31 timing is flexible; many users prefer morning administration

Important Considerations

• Mitochondrial health responds most dramatically to exercise, especially zone 2 aerobic work. Peptides without training yield a fraction of the benefit.
• NAD+ precursors modestly increase methylation demand; ensuring adequate B-vitamin and methyl donor status (folate, B12, TMG) is prudent.
• Individuals with diagnosed primary mitochondrial disease should be managed by a specialist; this protocol is not a substitute.
• MOTS-c can improve insulin sensitivity — diabetics using insulin or sulfonylureas must monitor glucose closely and coordinate with their clinician.
• SS-31 is expensive; budget-constrained users often prioritize MOTS-c and NAD+ precursor first.
• Pregnancy, active malignancy, and certain inherited metabolic diseases are reasons to avoid this protocol without specialist oversight.
• Do not expect acute stimulant-like energy; mitochondrial improvements accrue over weeks to months.

Disclaimer

This content is educational and informational only. It is not medical advice and does not recommend the use of any peptide or supplement. Several compounds referenced (MOTS-c, SS-31, NMN in some markets) are not FDA-approved for human use and are sold as research chemicals in most jurisdictions. Consult a qualified clinician before starting any supplementation or peptide protocol, particularly if you have a mitochondrial, metabolic, cardiovascular, or renal condition. Pepperpedia does not endorse the acquisition or use of unapproved substances.